^
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/15/2021
Initiation :
10/20/2021
Primary completion :
12/30/2028
Completion :
12/30/2029
PD-L1
|
PD-L1 expression
|
azacitidine • bintrafusp alfa (M7824)
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/15/2021
Initiation :
05/09/2019
Primary completion :
09/15/2022
Completion :
09/15/2022
PD-L1
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/15/2021
Initiation :
04/04/2019
Primary completion :
08/31/2022
Completion :
08/31/2022
MSI • IL2
|
Opdivo (nivolumab) • CMAB 819 (nivolumab biosimilar)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/15/2021
Initiation :
04/12/2019
Primary completion :
02/28/2023
Completion :
02/28/2023
PD-L1 • CD4
|
Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)
Phase 2
Elevation Oncology
Recruiting
Last update posted :
10/14/2021
Initiation :
09/29/2020
Primary completion :
06/01/2022
Completion :
06/01/2023
NRG1
|
NRG1 fusion
|
seribantumab (MM-121)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/14/2021
Initiation :
06/25/2018
Primary completion :
06/30/2025
Completion :
06/30/2025
RB1
|
Ibrance (palbociclib)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/14/2021
Initiation :
07/13/2020
Primary completion :
09/30/2027
Completion :
09/30/2027
ALB
|
Zarnestra (tipifarnib)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/14/2021
Initiation :
09/28/2018
Primary completion :
12/31/2021
Completion :
12/31/2021
PD-L1 • CD4
|
PD-L1 expression
|
Tecentriq (atezolizumab) • glycosylated recombinant human interleukin-7 (CYT107)
Phase 1/2
BeiGene
Recruiting
Last update posted :
10/13/2021
Initiation :
11/13/2018
Primary completion :
07/01/2023
Completion :
01/01/2024
PD-L1
|
PD-L1 expression
|
Baize’an (tislelizumab) • BGB-A425
Phase 2
Astellas Pharma Global Development, Inc.
Active, not recruiting
Last update posted :
10/13/2021
Initiation :
10/08/2017
Primary completion :
10/27/2020
Completion :
05/31/2025
PD-L1 • PD-1
|
cisplatin • Padcev (enfortumab vedotin)
Phase N/A
Pfizer
Recruiting
Last update posted :
10/13/2021
Initiation :
09/15/2021
Primary completion :
12/31/2021
Completion :
01/31/2022
CRP
|
Bavencio (avelumab) • Inlyta (axitinib)
Phase 1a/1b
Genentech, Inc.
Recruiting
Last update posted :
10/12/2021
Initiation :
12/21/2017
Primary completion :
02/01/2024
Completion :
02/01/2024
HER-2 • ER • PGR
|
HER-2 negative • PGR negative
|
Tecentriq (atezolizumab) • autogene cevumeran (RG6180)
Phase 1b
NeoTX Therapeutics Ltd.
Recruiting
Last update posted :
10/11/2021
Initiation :
10/10/2019
Primary completion :
04/01/2022
Completion :
07/28/2022
HER-2 • ER • TPBG
|
HER-2 negative • TPBG positive
|
Imfinzi (durvalumab) • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)
Phase 1
Janssen Research & Development, LLC
Not yet recruiting
Last update posted :
10/08/2021
Initiation :
10/18/2021
Primary completion :
02/22/2024
Completion :
02/22/2024
MSI
|
MSI-H/dMMR
|
JNJ-78306358
Phase 2
Zhen Wang, MD
Recruiting
Last update posted :
10/08/2021
Initiation :
01/15/2019
Primary completion :
12/31/2026
Completion :
12/31/2026
LDHA
Phase 1
M.D. Anderson Cancer Center
Recruiting
Last update posted :
10/08/2021
Initiation :
08/20/2020
Primary completion :
01/31/2022
Completion :
01/31/2022
PD-L1 • TP53 • PTEN • RB1
|
Yervoy (ipilimumab) • valemetostat (DS-3201)
Phase 1b
Janssen Research & Development, LLC
Recruiting
Last update posted :
10/08/2021
Initiation :
11/10/2020
Primary completion :
04/03/2023
Completion :
12/29/2024
EGFR • MET
|
Lispro-PH20 (insulin lispro/rHuPH20) • amivantamab SC (Ami-LC)
Phase 1
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
10/08/2021
Initiation :
12/03/2021
Primary completion :
09/01/2023
Completion :
09/01/2023
FGFR2
|
Balversa (erdafitinib) • Padcev (enfortumab vedotin)
Phase 2
BeiGene
Recruiting
Last update posted :
10/07/2021
Initiation :
09/18/2021
Primary completion :
12/01/2023
Completion :
12/01/2024
PD-L1
|
lenvatinib • Baize’an (tislelizumab)
Phase 3
Nektar Therapeutics
Active, not recruiting
Last update posted :
10/07/2021
Initiation :
12/18/2018
Primary completion :
12/01/2021
Completion :
06/01/2024
PD-L1
|
Opdivo (nivolumab) • Sutent (sunitinib) • Cabometyx (cabozantinib tablet) • bempegaldesleukin (NKTR-214)
Phase 2
Case Comprehensive Cancer Center
Active, not recruiting
Last update posted :
10/07/2021
Initiation :
12/30/2015
Primary completion :
08/21/2019
Completion :
08/21/2023
PD-1
|
Inlyta (axitinib)
Phase 1
Fate Therapeutics
Not yet recruiting
Last update posted :
10/06/2021
Initiation :
10/15/2021
Primary completion :
09/05/2023
Completion :
08/05/2025
KRAS • TMB • NRAS • MSI
|
KRAS mutation • TMB-H • MSI-H/dMMR • NRAS mutation
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • fludarabine IV • FT538
Phase 2
UNICANCER
Completed
Last update posted :
10/06/2021
Initiation :
01/01/2016
Primary completion :
06/01/2018
Completion :
06/30/2021
IL2 • IFNA1
|
Opdivo (nivolumab)
Phase 2
Peter MacCallum Cancer Centre, Australia
Not yet recruiting
Last update posted :
10/06/2021
Initiation :
11/01/2021
Primary completion :
12/01/2023
Completion :
12/01/2023
PD-L1 • CD8 • PD-L2 • CD4
|
PD-L1 expression
|
Keytruda (pembrolizumab)
Phase 1b/2
Pharmacyclics LLC.
Completed
Last update posted :
10/05/2021
Initiation :
11/01/2015
Primary completion :
08/20/2021
Completion :
08/20/2021
EGFR • KRAS
|
EGFR expression
|
Keytruda (pembrolizumab) • Erbitux (cetuximab) • ibrutinib • paclitaxel • everolimus • docetaxel
Phase 2
National Cancer Institute (NCI)
Suspended
Last update posted :
10/05/2021
Initiation :
10/09/2018
Primary completion :
06/30/2031
Completion :
06/30/2031
TFE3
|
TFEB translocation
|
Opdivo (nivolumab) • Inlyta (axitinib) • CMAB 819 (nivolumab biosimilar)
Phase 2
M.D. Anderson Cancer Center
Not yet recruiting
Last update posted :
10/04/2021
Initiation :
12/31/2021
Primary completion :
04/25/2023
Completion :
04/25/2023
PD-L1
|
everolimus • lenvatinib • Cabometyx (cabozantinib tablet)
Phase 3
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
10/04/2021
Initiation :
02/27/2020
Primary completion :
09/17/2025
Completion :
09/17/2025
PD-L1
|
everolimus • Welireg (belzutifan)
Phase 1/2
Bristol-Myers Squibb
Recruiting
Last update posted :
10/04/2021
Initiation :
09/11/2020
Primary completion :
12/26/2024
Completion :
01/17/2026
PD-L1
|
Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Inlyta (axitinib) • bempegaldesleukin (NKTR-214)
Phase 1b
ADC Therapeutics S.A.
Recruiting
Last update posted :
10/04/2021
Initiation :
11/09/2018
Primary completion :
11/15/2022
Completion :
11/15/2023
MSI
|
Keytruda (pembrolizumab) • camidanlumab tesirine (ADCT-301)
Phase 2
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
10/04/2021
Initiation :
09/13/2020
Primary completion :
10/04/2025
Completion :
10/04/2025
CTLA4
|
Welireg (belzutifan)
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
10/04/2021
Initiation :
07/09/2015
Primary completion :
09/30/2022
Completion :
09/30/2022
PD-L1 • MET
|
PD-L1 expression • MET expression
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)
Phase 1
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
10/04/2021
Initiation :
07/11/2018
Primary completion :
11/18/2024
Completion :
11/18/2024
HER-2
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • lenvatinib • pemetrexed • MK-4830
Phase 2
University of Wisconsin, Madison
Completed
Last update posted :
10/01/2021
Initiation :
06/08/2018
Primary completion :
06/29/2021
Completion :
06/29/2021
FOLH1 • CD31 • ENG
|
FOLH1 expression
Phase N/A
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/01/2021
Initiation :
05/13/2002
FLCN
Phase 2
Novartis Pharmaceuticals
Recruiting
Last update posted :
09/30/2021
Initiation :
08/28/2017
Primary completion :
03/31/2022
Completion :
06/17/2022
EGFR • BRAF
|
BRAF V600E • EGFR mutation • EGFR T790M
|
spartalizumab (PDR001) • taminadenant (NIR178)
Phase 1/2
Nektar Therapeutics
Active, not recruiting
Last update posted :
09/29/2021
Initiation :
03/15/2018
Primary completion :
09/01/2021
Completion :
12/01/2021
PD-L1 • PD-1
|
Opdivo (nivolumab) • bempegaldesleukin (NKTR-214) • NKTR-262
Phase 1
Pfizer
Not yet recruiting
Last update posted :
09/29/2021
Initiation :
10/01/2021
Primary completion :
07/07/2024
Completion :
07/07/2024
IL2
|
sasanlimab (PF-06801591) • PF-07263689
Phase 1
Y Biologics Inc.
Recruiting
Last update posted :
09/29/2021
Initiation :
07/01/2020
Primary completion :
09/30/2022
Completion :
05/23/2023
EGFR • PD-L1 • ALK • TMB • MSI
|
PD-L1 expression • TMB-H • MSI-H/dMMR • ALK translocation
|
YBL-006
Phase 2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
09/28/2021
Initiation :
09/23/2021
Primary completion :
06/30/2023
Completion :
06/30/2023
BRAF
|
EGFR mutation • BRAF mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR T790M negative
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Actemra IV (tocilizumab) • Actemra SC (tocilizumab SC)
Phase 
Guardant Health, Inc.
Recruiting
Last update posted :
09/28/2021
Initiation :
09/07/2021
Primary completion :
10/01/2027
Completion :
10/01/2027
HER-2
Phase 2
University of Florida
Suspended
Last update posted :
09/27/2021
Initiation :
08/13/2018
Primary completion :
12/01/2022
Completion :
12/01/2023
PTEN • IDH1 • IDH2 • ARID1A • BAP1 • CDK4 • POLD1 • BRIP1 • CHEK2 • RAD51 • CHEK1 • RAD50 • BARD1 • CDK2 • RAD52 • WRN • BACH1 • FANCG • NBN • PRKDC • RPA1 • ABRAXAS1 • FEN1
|
BARD1 mutation • WRN mutation • RPA1 mutation
|
Zejula (niraparib)
Phase 1/2
Jason J. Luke, MD
Recruiting
Last update posted :
09/24/2021
Initiation :
06/11/2020
Primary completion :
11/30/2021
Completion :
11/30/2021
CD4
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • pexmetinib (ARRY-614)
Phase 2
Epizyme, Inc.
Recruiting
Last update posted :
09/24/2021
Initiation :
12/22/2015
Primary completion :
05/01/2023
Completion :
05/01/2023
CD34 • SS18
|
SMARCA4 mutation
|
Tazverik (tazemetostat)
Phase 1
Xencor, Inc.
Recruiting
Last update posted :
09/22/2021
Initiation :
05/01/2019
Primary completion :
07/01/2023
Completion :
12/01/2024
HER-2 • ER • PGR
|
HER-2 negative
|
Yervoy (ipilimumab) • izuralimab (XmAb23104)
Phase 2
Incyte Corporation
Active, not recruiting
Last update posted :
09/22/2021
Initiation :
01/09/2019
Primary completion :
10/30/2020
Completion :
07/06/2022
PD-L1 • ALK
|
PD-L1 expression • PD-L1 overexpression
|
retifanlimab (INCMGA0012)
Phase 1
AO GENERIUM
Recruiting
Last update posted :
09/22/2021
Initiation :
07/22/2020
Primary completion :
04/22/2024
Completion :
06/15/2024
PD-1
|
GNR-051
Phase 1
Incyte Corporation
Active, not recruiting
Last update posted :
09/22/2021
Initiation :
09/24/2018
Primary completion :
09/30/2021
Completion :
09/30/2021
HAVCR2
|
INCAGN2390
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/21/2021
Initiation :
11/04/2020
Primary completion :
11/02/2025
Completion :
11/02/2025
CD4
|
Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CMAB 819 (nivolumab biosimilar)
Phase 1a/1b
OncoC4, Inc.
Recruiting
Last update posted :
09/21/2021
Initiation :
09/16/2020
Primary completion :
12/31/2022
Completion :
12/31/2023
EGFR
|
EGFR mutation
|
Keytruda (pembrolizumab) • Tagrisso (osimertinib) • ONC-392
Phase 1
Pfizer
Recruiting
Last update posted :
09/21/2021
Initiation :
09/24/2020
Primary completion :
12/25/2023
Completion :
12/25/2023
PD-L1
|
PD-L1 expression
|
Inlyta (axitinib) • sasanlimab (PF-06801591) • PF-07265807
Phase 1
Pfizer
Recruiting
Last update posted :
09/20/2021
Initiation :
11/13/2019
Primary completion :
01/06/2024
Completion :
01/06/2024
PD-1
|
sasanlimab (PF-06801591) • PF-06940434
Phase 1
Emory University
Recruiting
Last update posted :
09/17/2021
Initiation :
08/24/2020
Primary completion :
08/01/2022
Completion :
08/01/2022
IL6 • CXCL8 • TNFA • IL2 • CSF2 • IL10 • IL1A • IL1B
|
ketorolac ophthalmic
Phase 2
Infinity Pharmaceuticals, Inc.
Recruiting
Last update posted :
09/15/2021
Initiation :
12/17/2019
Primary completion :
08/01/2022
Completion :
08/01/2022
HER-2 • PD-L1 • ER • PGR
|
PD-L1 expression • HER-2 negative
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • Abraxane (albumin-bound paclitaxel) • eganelisib (IPI-549)
Phase 1b
Hoffmann-La Roche
Completed
Last update posted :
09/13/2021
Initiation :
03/27/2017
Primary completion :
06/15/2021
Completion :
06/15/2021
PD-L1
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • simlukafusp alfa (RG7461)
Phase 1
Novartis Pharmaceuticals
Not yet recruiting
Last update posted :
09/13/2021
Initiation :
09/30/2021
Primary completion :
02/24/2025
Completion :
02/24/2025
VHL • EPAS1 • SDHB • SDHC • SDHA • SDHAF2 • SDHD
|
VHL mutation • SDHB mutation
|
everolimus • spartalizumab (PDR001) • DFF332 • taminadenant (NIR178)
Phase 2
Universitätsmedizin Mannheim
Recruiting
Last update posted :
09/13/2021
Initiation :
06/15/2020
Primary completion :
12/15/2021
Completion :
03/15/2022
VEGFA • IL6 • TNFA • IL1B • CRP
Phase 1b/2
Aravive, Inc.
Recruiting
Last update posted :
09/10/2021
Initiation :
02/26/2021
Primary completion :
12/01/2022
Completion :
07/01/2023
GAS6
|
Cabometyx (cabozantinib tablet) • batiraxcept (AVB-500)
Phase N/A
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
09/10/2021
Initiation :
03/30/2016
Primary completion :
03/01/2023
Completion :
03/01/2023
IL2
|
tremelimumab (CP-675206)
Phase 1b/2
Sumitomo Dainippon Pharma Oncology, Inc
Recruiting
Last update posted :
09/10/2021
Initiation :
12/14/2017
Primary completion :
08/01/2023
Completion :
02/01/2024
MSI • HLA-A
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • adegramotide/nelatimotide (DSP-7888)
Phase 1
The Methodist Hospital Research Institute
Recruiting
Last update posted :
09/09/2021
Initiation :
08/03/2018
Primary completion :
10/31/2021
Completion :
01/28/2022
BRAF • PD-L1 • TMB • MSI
|
PD-L1 expression • TMB-H • MSI-H/dMMR • BRAF mutation
|
Keytruda (pembrolizumab)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
09/08/2021
Initiation :
05/08/2017
Primary completion :
06/30/2021
Completion :
07/01/2022
MET • RET • AXL
|
MET amplification • MET overexpression • RET mutation • RET rearrangement • MET mutation • AXL overexpression
|
Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
Phase 2
Bayer
Recruiting
Last update posted :
09/08/2021
Initiation :
09/30/2015
Primary completion :
08/15/2023
Completion :
09/30/2025
NTRK1 • NTRK3 • NTRK2 • NTRK
|
NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • NTRK fusion
|
Vitrakvi (larotrectinib)
Phase 
VastBiome
Not yet recruiting
Last update posted :
09/08/2021
Initiation :
09/14/2021
Primary completion :
09/14/2023
Completion :
09/14/2028
IFNG • TNFA • IL2 • IL10
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/08/2021
Initiation :
12/29/2020
Primary completion :
12/01/2023
Completion :
12/01/2023
BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • HRD • BAP1 • CDK12 • RAD51B • BRIP1 • CHEK2 • FANCA • RAD51 • RAD51C • RAD51D • CHEK1 • RAD50 • RAD54L • BARD1 • FANCF • FANCL • FANCI • FANCM • BACH1 • FANCD2 • FANCG • NBN • FANCC
|
BRCA1 mutation • BRCA2 mutation • ATM mutation
|
Talzenna (talazoparib)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/08/2021
Initiation :
05/10/2018
Primary completion :
08/30/2022
Completion :
08/30/2022
SETD2
|
SETD2 mutation
|
adavosertib (AZD1775)
Phase N/A
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/03/2021
Initiation :
02/24/2003
FH
|
FH mutation
Phase 2
Gregory Daniels
Recruiting
Last update posted :
09/03/2021
Initiation :
05/23/2019
Primary completion :
08/01/2022
Completion :
08/01/2024
PD-L1
|
Opdivo (nivolumab)
Phase N/A
Pfizer
Recruiting
Last update posted :
09/01/2021
Initiation :
05/21/2015
Primary completion :
12/01/2021
Completion :
12/01/2021
VEGFA • FGF
|
Sutent (sunitinib)
Phase 2
Sunnybrook Health Sciences Centre
Completed
Last update posted :
09/01/2021
Initiation :
12/01/2016
Primary completion :
08/01/2021
Completion :
08/05/2021
PD-L1
|
Keytruda (pembrolizumab)
Phase 2
Lytix Biopharma AS
Recruiting
Last update posted :
09/01/2021
Initiation :
06/01/2021
Primary completion :
12/31/2022
Completion :
08/31/2023
BRAF • MSI • BRCA
|
PD-L1 expression • MSI-H/dMMR • BRAF mutation • BRCA mutation
|
Keytruda (pembrolizumab) • cisplatin • Oncopore (ruxotemitide)
Phase 1/2
Klus Pharma Inc.
Recruiting
Last update posted :
09/01/2021
Initiation :
07/16/2018
Primary completion :
04/01/2022
Completion :
12/01/2022
HER-2
|
HER-2 positive • HER-2 expression • HER-2 underexpression
|
A166
Phase N/A
Chugai Pharmaceutical
Completed
Last update posted :
08/30/2021
Initiation :
12/16/2018
Primary completion :
07/21/2021
Completion :
07/21/2021
PD-L1
|
PD-L1 expression • PD-L1 negative
Phase 2
Hoffmann-La Roche
Recruiting
Last update posted :
08/30/2021
Initiation :
11/19/2015
Primary completion :
12/01/2022
Completion :
12/02/2024
NTRK1 • NTRK3 • ROS1 • NTRK2
|
ALK rearrangement • ROS1 rearrangement
|
Xalkori (crizotinib) • Rozlytrek (entrectinib)
Phase N/A
Rutgers, The State University of New Jersey
Recruiting
Last update posted :
08/30/2021
Initiation :
09/01/2017
Primary completion :
08/31/2021
Completion :
08/31/2021
NFKB1
Phase 2
Dana-Farber Cancer Institute
Recruiting
Last update posted :
08/27/2021
Initiation :
08/14/2020
Primary completion :
10/01/2023
Completion :
10/01/2025
SMARCB1
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
Phase 1
Neil M Rofsky, MD, MHA
Recruiting
Last update posted :
08/27/2021
Initiation :
08/18/2021
Primary completion :
08/18/2025
Completion :
08/18/2026
EPAS1
|
PT2385
Phase 1
Cellex Patient Treatment GmbH
Recruiting
Last update posted :
08/25/2021
Initiation :
11/23/2020
Primary completion :
11/01/2022
Completion :
05/01/2023
FOLH1
|
FOLH1 expression
|
fludarabine IV • cyclophosphamide intravenous
Phase 1
Chang Gung Memorial Hospital
Recruiting
Last update posted :
08/25/2021
Initiation :
04/09/2021
Primary completion :
06/30/2022
Completion :
06/30/2023
HER-2
|
HER-2 positive
Phase 2b
ImmunityBio, Inc.
Active, not recruiting
Last update posted :
08/25/2021
Initiation :
12/11/2018
Primary completion :
05/01/2023
Completion :
12/01/2023
BRAF • PD-L1 • ALK • MSI
|
PD-L1 expression • BRAF V600E • MSI-H/dMMR • PD-L1 overexpression • BRAF V600
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Bavencio (avelumab) • Anktiva (inbakicept) • PD-L1.t-haNK
Phase 1
Novartis Pharmaceuticals
Recruiting
Last update posted :
08/24/2021
Initiation :
05/22/2019
Primary completion :
10/09/2023
Completion :
04/01/2025
CRP
|
Avastin (bevacizumab) • paclitaxel • 5-fluorouracil • oxaliplatin • Cyramza (ramucirumab) • irinotecan • Cabometyx (cabozantinib tablet) • leucovorin calcium • gevokizumab (S 78989)
Phase 1
Telix International Pty Ltd
Completed
Last update posted :
08/24/2021
Initiation :
08/01/2020
Primary completion :
10/27/2020
Completion :
04/06/2021
CA9
|
CA9 expression
|
Rencarex (girentuximab)
Phase 2
University of Texas Southwestern Medical Center
Completed
Last update posted :
08/23/2021
Initiation :
10/02/2013
Primary completion :
08/25/2020
Completion :
04/20/2021
IL2
Phase 1
SCRI Development Innovations, LLC
Active, not recruiting
Last update posted :
08/23/2021
Initiation :
09/22/2015
Primary completion :
07/31/2021
Completion :
03/01/2022
MET
|
Avastin (bevacizumab) • Tabrecta (capmatinib)
Phase 3
Pfizer
Active, not recruiting
Last update posted :
08/19/2021
Initiation :
03/23/2016
Primary completion :
05/21/2024
Completion :
05/21/2024
PD-L1 • CD8
|
PD-L1 expression
|
Sutent (sunitinib) • Bavencio (avelumab) • Inlyta (axitinib)
Phase 1
Xencor, Inc.
Recruiting
Last update posted :
08/18/2021
Initiation :
05/29/2019
Primary completion :
06/01/2024
Completion :
11/01/2025
HER-2 • PD-L1 • ER • PGR
|
HER-2 negative
|
Keytruda (pembrolizumab) • pavunalimab (XmAb22841)
Phase 3
AstraZeneca
Active, not recruiting
Last update posted :
08/17/2021
Initiation :
07/25/2017
Primary completion :
08/18/2019
Completion :
12/31/2021
VHL
|
VHL mutation
|
Sutent (sunitinib) • Orpathys (savolitinib)
Phase 2
SOLTI Breast Cancer Research Group
Recruiting
Last update posted :
08/16/2021
Initiation :
04/12/2021
Primary completion :
12/31/2023
Completion :
12/11/2024
PD-1
|
PD-1 expression
|
spartalizumab (PDR001)
Phase 1
AstraZeneca
Recruiting
Last update posted :
08/16/2021
Initiation :
08/18/2020
Primary completion :
09/07/2023
Completion :
09/07/2023
FOXP3
|
FOXP3 expression
|
Imfinzi (durvalumab) • AZD8701
Phase 1/2
Gilead Sciences
Completed
Last update posted :
08/12/2021
Initiation :
12/17/2012
Primary completion :
03/01/2019
Completion :
08/13/2020
HER-2
|
HER-2 negative
|
Trodelvy (sacituzumab govitecan-hziy)
Phase 1
Shattuck Labs, Inc.
Recruiting
Last update posted :
08/12/2021
Initiation :
03/26/2019
Primary completion :
02/02/2022
Completion :
04/05/2022
EGFR • ALK • MSI
|
EGFR mutation • MSI-H/dMMR • ALK fusion
|
TAK-252
Phase 1
University of Florida
Recruiting
Last update posted :
08/11/2021
Initiation :
01/10/2020
Primary completion :
01/01/2022
Completion :
10/01/2023
MSI
|
MSI-H/dMMR
|
Keytruda (pembrolizumab)
Phase 2
Washington University School of Medicine
Recruiting
Last update posted :
08/10/2021
Initiation :
07/29/2020
Primary completion :
07/31/2024
Completion :
07/31/2025
TSC1 • SDHB
|
TSC1 deletion
|
Keytruda (pembrolizumab) • lenvatinib
Phase 2
Don Dizon
Recruiting
Last update posted :
08/09/2021
Initiation :
04/30/2018
Primary completion :
12/01/2021
Completion :
02/01/2023
PD-L1
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
Phase 3
Telix International Pty Ltd
Recruiting
Last update posted :
08/06/2021
Initiation :
08/15/2019
Primary completion :
12/31/2021
Completion :
05/30/2022
CA9
|
CA9 expression
|
Rencarex (girentuximab)
Phase 1
GEMoaB GmbH
Recruiting
Last update posted :
08/05/2021
Initiation :
04/15/2019
Primary completion :
06/01/2022
Completion :
12/01/2022
PSCA
|
GEM3PSCA
Phase 2
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
08/05/2021
Initiation :
08/22/2019
Primary completion :
08/01/2023
Completion :
08/01/2023
PD-L1
|
VHL mutation
|
Bavencio (avelumab) • Talzenna (talazoparib)
Phase 2
AIO-Studien-gGmbH
Active, not recruiting
Last update posted :
08/04/2021
Initiation :
10/01/2016
Primary completion :
12/01/2018
Completion :
09/01/2022
CD8 • PD-1 • IFNG • PD-L2 • IL2RA • CD14 • CD27 • CD69 • FAS • IL10 • IL17A • ICOS • ITGAM • FOXP3 • LAMP1
|
PD-L1 expression
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
Phase 1
Jonsson Comprehensive Cancer Center
Completed
Last update posted :
08/04/2021
Initiation :
01/14/2013
Primary completion :
07/03/2018
Completion :
05/27/2021
CA9
|
DC-AdGMCAIX
Phase 2
Centre hospitalier de l'Université de Montréal ...
Active, not recruiting
Last update posted :
08/04/2021
Initiation :
06/02/2017
Primary completion :
01/01/2022
Completion :
06/01/2022
PD-L1
|
PD-L1 expression
|
Opdivo (nivolumab)
Phase 1a
HiberCell, Inc.
Recruiting
Last update posted :
08/02/2021
Initiation :
06/08/2021
Primary completion :
03/01/2022
Completion :
04/01/2022
HER-2
|
EGFR positive
|
HC-5404-FU
Phase 1a
Simcha IL-18, Inc.
Recruiting
Last update posted :
07/29/2021
Initiation :
07/08/2021
Primary completion :
05/30/2023
Completion :
07/30/2023
TMB • MSI
|
TMB-H • MSI-H/dMMR
|
ST-067
Phase N/A
Merus N.V.
Available
Last update posted :
07/28/2021
NRG1
|
NRG1 fusion • NRG1 fusion
|
zenocutuzumab (MCLA-128)
Phase 1b
Pfizer
Completed
Last update posted :
07/28/2021
Initiation :
09/16/2014
Primary completion :
03/31/2017
Completion :
07/03/2019
PD-L1 • mTOR • KDR • CXCL8 • FLT1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • Inlyta (axitinib)
Phase 2
ImaginAb, Inc.
Recruiting
Last update posted :
07/28/2021
Initiation :
12/18/2018
Primary completion :
03/01/2022
Completion :
12/01/2022
CD8
Phase 1
Corvus Pharmaceuticals, Inc.
Recruiting
Last update posted :
07/27/2021
Initiation :
04/25/2018
Primary completion :
03/01/2022
Completion :
12/01/2023
MSI
|
Keytruda (pembrolizumab) • ciforadenant (CPI-444) • mupadolimab (CPI-006)
Phase 1/2
Dragonfly Therapeutics
Recruiting
Last update posted :
07/26/2021
Initiation :
07/10/2020
Primary completion :
09/01/2022
Completion :
12/01/2024
EGFR • HER-2 • BRAF • ALK • ER • PGR • ROS1
|
EGFR mutation • BRAF mutation • BRAF V600 • HER-2 negative • RET mutation • ER negative • PGR negative
|
Opdivo (nivolumab) • DF6002
Phase 1/2
Actuate Therapeutics Inc.
Recruiting
Last update posted :
07/23/2021
Initiation :
01/04/2019
Primary completion :
11/01/2022
Completion :
11/01/2023
HER-2 • BCL2
|
carboplatin • gemcitabine • Abraxane (albumin-bound paclitaxel) • irinotecan • pegylated liposomal doxorubicin • lomustine • 9-ING-41
Phase 2
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
07/23/2021
Initiation :
12/13/2017
Primary completion :
07/31/2022
Completion :
07/31/2023
SMARCB1
|
SMARCB1 negative
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
Phase 1
Jounce Therapeutics, Inc.
Recruiting
Last update posted :
07/23/2021
Initiation :
01/12/2021
Primary completion :
09/01/2023
Completion :
01/01/2024
EGFR • PD-L1 • ALK
|
EGFR mutation • ALK rearrangement
|
JTX-8064 • pimivalimab (JTX-4014)
Phase 2
Yale University
Not yet recruiting
Last update posted :
07/23/2021
Initiation :
09/01/2021
Primary completion :
01/01/2025
Completion :
01/01/2026
BRAF
|
BRAF mutation
|
Keytruda (pembrolizumab) • lenvatinib
Phase 1
Inhibrx, Inc.
Recruiting
Last update posted :
07/22/2021
Initiation :
01/30/2019
Primary completion :
11/01/2022
Completion :
03/01/2023
EGFR • ALK
|
EGFR mutation • ALK rearrangement
|
Keytruda (pembrolizumab) • INBRX-105
Phase N/A
Arbeitsgemeinschaft medikamentoese Tumortherapie
Recruiting
Last update posted :
07/21/2021
Initiation :
03/30/2017
Primary completion :
12/01/2021
Completion :
12/01/2021
TMB
Phase 1/2
Tarus Therapeutics, Inc.
Not yet recruiting
Last update posted :
07/20/2021
Initiation :
09/15/2021
Primary completion :
06/01/2023
Completion :
09/30/2023
CD4
|
TT-10
Phase 1
Inhibrx, Inc.
Recruiting
Last update posted :
07/20/2021
Initiation :
12/10/2019
Primary completion :
12/02/2022
Completion :
03/15/2023
EGFR • PD-L1 • ALK
|
EGFR mutation • ALK rearrangement
|
Keytruda (pembrolizumab) • INBRX-106
Phase 1
The Affiliated Hospital of Xuzhou Medical Unive...
Recruiting
Last update posted :
07/20/2021
Initiation :
10/01/2021
Primary completion :
09/30/2025
Completion :
09/30/2026
CA9
Phase N/A
Hospices Civils de Lyon
Recruiting
Last update posted :
07/16/2021
Initiation :
12/04/2018
Primary completion :
01/04/2028
Completion :
01/04/2028
MUC16
|
BRAF V600E • EGFR mutation • BRAF V600 • ALK fusion • ROS1 fusion • ALK-ROS1 fusion
|
cisplatin
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
07/16/2021
Initiation :
01/19/2018
Primary completion :
01/31/2022
Completion :
01/31/2022
PD-L1 • CD4
|
PD-L1 expression
|
cisplatin • Tecentriq (atezolizumab) • Halaven (eribulin mesylate)
Phase 2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
07/15/2021
Initiation :
08/17/2018
Primary completion :
01/31/2024
Completion :
01/31/2024
IL6 • SMARCB1
|
SMARCB1 negative
|
gemcitabine • doxorubicin hydrochloride • Ninlaro (ixazomib) • daunorubicin • liposomal gemcitabine (FF-10832)
Phase 1/2
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
07/15/2021
Initiation :
04/06/2020
Primary completion :
10/01/2022
Completion :
10/01/2022
PD-L1 • PD-1
|
Talzenna (talazoparib) • Inlyta (axitinib)
Phase 1/2
University of Michigan Rogel Cancer Center
Completed
Last update posted :
07/13/2021
Initiation :
03/16/2017
Primary completion :
02/25/2019
Completion :
06/23/2020
IL2
|
Opdivo (nivolumab)
Phase 2
Jonsson Comprehensive Cancer Center
Not yet recruiting
Last update posted :
07/09/2021
Initiation :
12/30/2021
Primary completion :
08/01/2023
Completion :
08/01/2024
FH
|
temozolomide • Partruvix (pamiparib)
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
07/09/2021
Initiation :
11/23/2011
Primary completion :
02/14/2020
BECN1
|
MK-2206 • hydroxychloroquine
Phase 1
Novartis Pharmaceuticals
Completed
Last update posted :
07/08/2021
Initiation :
04/25/2017
Primary completion :
06/18/2021
Completion :
06/18/2021
CD8
|
TILs
|
spartalizumab (PDR001) • NIS793
Phase 2
M.D. Anderson Cancer Center
Not yet recruiting
Last update posted :
07/07/2021
Initiation :
11/01/2021
Primary completion :
12/31/2023
Completion :
12/31/2023
ARID1A • CXCL13
|
ARID1A mutation
|
Opdivo (nivolumab)
Phase 1
University of Washington
Recruiting
Last update posted :
07/05/2021
Initiation :
08/28/2018
Primary completion :
12/17/2022
Completion :
12/17/2023
PD-L1 • CTLA4
|
Keytruda (pembrolizumab) • Proleukin (aldesleukin)
Phase 1
Novartis Pharmaceuticals
Active, not recruiting
Last update posted :
07/02/2021
Initiation :
10/14/2016
Primary completion :
09/16/2021
Completion :
08/17/2022
CD8 • FOXP3
|
TILs
|
everolimus • Farydak (panobinostat) • spartalizumab (PDR001) • LCL161 • QBM076 • siremadlin (HDM201)
Phase N/A
Changhua Christian Hospital
Recruiting
Last update posted :
07/01/2021
Initiation :
02/01/2019
Primary completion :
06/30/2022
Completion :
07/31/2022
CRP
Phase 
University Hospital, Strasbourg, France
Not yet recruiting
Last update posted :
06/30/2021
Initiation :
07/01/2021
Primary completion :
07/01/2022
Completion :
07/01/2022
MFI2
|
MFI2 expression
Phase 1/2
Genocea Biosciences, Inc.
Active, not recruiting
Last update posted :
06/25/2021
Initiation :
08/29/2018
Primary completion :
03/01/2022
Completion :
03/01/2022
PD-L1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • GEN-009
Phase 1/2
National Cancer Institute (NCI)
Completed
Last update posted :
06/24/2021
Initiation :
02/07/2014
Primary completion :
03/24/2021
Completion :
03/24/2021
GAPDH • MAGEA3
|
fludarabine IV • Proleukin (aldesleukin) • MAGE A3 TCR • cyclophosphamide intravenous
Phase 2
Michael B. Atkins, MD
Recruiting
Last update posted :
06/23/2021
Initiation :
04/24/2017
Primary completion :
09/01/2021
Completion :
09/01/2022
PD-L1
|
PD-L1 expression
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
Phase 2
City of Hope Medical Center
Completed
Last update posted :
06/22/2021
Initiation :
12/08/2010
Primary completion :
10/17/2013
Completion :
12/31/2013
IL6
|
Votrient (pazopanib)
Phase 1
Harbour BioMed US, Inc.
Recruiting
Last update posted :
06/21/2021
Initiation :
09/24/2019
Primary completion :
03/01/2023
Completion :
03/01/2023
BRAF
|
BRAF mutation • BRAF V600
|
HBM4003
Phase 1
Rutgers, The State University of New Jersey
Completed
Last update posted :
06/18/2021
Initiation :
08/17/2017
Primary completion :
01/08/2020
Completion :
01/30/2020
EGFR • PD-L1 • ALK
|
PD-L1 expression • PD-L1 overexpression
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • troriluzole (BHV-4157)
Phase 1a/1b
Pionyr Immunotherapeutics Inc.
Recruiting
Last update posted :
06/16/2021
Initiation :
10/29/2020
Primary completion :
10/28/2023
Completion :
10/28/2023
HER-2 • PD-L1
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • PY314
Phase N/A
Duke University
Recruiting
Last update posted :
06/10/2021
Initiation :
03/07/2017
Primary completion :
12/01/2021
Completion :
12/01/2021
PD-L1 • PD-1 • LAG3 • CTLA4 • CD27
|
TILs
Phase 1
Apollomics (Australia) Pty. Ltd.
Active, not recruiting
Last update posted :
06/09/2021
Initiation :
03/27/2017
Primary completion :
12/01/2021
Completion :
06/01/2022
MSI
|
MSI-H/dMMR
|
geptanolimab (GB226)
Phase 1
Calico Life Sciences LLC
Recruiting
Last update posted :
06/07/2021
Initiation :
03/09/2021
Primary completion :
10/30/2023
Completion :
02/22/2024
PD-L1
|
PD-L1 expression
|
ABBV-CLS-484
Phase 1
Exelixis
Recruiting
Last update posted :
06/07/2021
Initiation :
03/20/2019
Primary completion :
11/01/2023
Completion :
11/01/2024
HER-2 • PD-L1
|
HR positive
|
Tecentriq (atezolizumab) • Bavencio (avelumab) • XL092
Phase N/A
University of Alabama at Birmingham
Recruiting
Last update posted :
06/04/2021
Initiation :
10/15/2020
Primary completion :
12/31/2021
Completion :
05/31/2022
TNFA • IGF1
Phase N/A
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
06/03/2021
Initiation :
05/01/2009
Primary completion :
05/31/2023
Completion :
05/31/2023
GSTM1
Phase 2
Beth Israel Deaconess Medical Center
Completed
Last update posted :
06/02/2021
Initiation :
11/01/2006
Primary completion :
10/31/2013
Completion :
10/31/2013
PD-L1 • CD276 • CA9
|
Proleukin (aldesleukin)
Phase 1/2
LaNova Medicines Limited
Recruiting
Last update posted :
05/31/2021
Initiation :
05/20/2021
Primary completion :
07/30/2023
Completion :
08/30/2024
EGFR • MET
|
MET amplification • MET exon 14 mutation • MET mutation • MET expression
|
LM-061
Phase 1/2
MedImmune LLC
Completed
Last update posted :
05/31/2021
Initiation :
05/19/2014
Primary completion :
03/17/2020
Completion :
03/17/2020
PD-L1
|
Opdivo (nivolumab) • Imfinzi (durvalumab) • MEDI0680
Phase N/A
R. Laura Vicente Vicente
Recruiting
Last update posted :
05/28/2021
Initiation :
05/19/2021
Primary completion :
04/23/2023
Completion :
12/30/2023
KIM1 • LCN2
Phase 1b/2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
05/26/2021
Initiation :
04/14/2021
Primary completion :
06/01/2025
Completion :
06/01/2025
MSI
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Bavencio (avelumab) • plinabulin (BPI 2358)
Phase 2
CCTU- Cancer Theme
Recruiting
Last update posted :
05/25/2021
Initiation :
07/27/2020
Primary completion :
04/25/2022
Completion :
04/25/2022
CD8 • IL2 • IFNA1
|
CD8 positive
|
Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)
Phase N/A
Massive Bio, Inc.
Recruiting
Last update posted :
05/25/2021
Initiation :
01/01/2018
Primary completion :
06/01/2022
Completion :
12/01/2022
EGFR • HER-2 • BRAF • PD-L1 • KRAS • ALK • ER • TP53 • ABL1 • FLT3 • TMB • NRAS • BRCA1 • BRCA2 • PTEN • FGFR2 • NTRK1 • NTRK3 • ROS1 • BCL2 • IDH1 • NTRK2 • IDH2 • HRAS • NPM1 • STK11 • DNMT3A • PDGFRA • RB1 • JAK2 • ERBB3 • NF1 • AKT1 • POLE • CCND1 • MCL1 • PDGFRB • KDR • PBRM1 • PTCH1 • BCL6 • PD-1 • BAP1 • VEGFA • MAP2K2 • MDM2 • MSH6 • CDK4 • FBXW7 • MSH2 • ATRX • CTNNB1 • FGFR4 • TSC2 • WT1 • ERBB4 • TSC1 • CLDN18 • JAK1 • PD-L2 • RAF1 • MDM4 • POLD1 • CHEK2 • FANCA • CEBPA • JAK3 • RICTOR • AURKA • MSH3 • TGFBR2 • CDK6 • CHEK1 • GATA6 • AKT2 • BRCA • CCND3 • MAP3K1 • MYCL • CCND2 • CSF1R • GNAS • HDAC1 • PARP1 • PRDM1 • ZNF217 • CDKN1A • ERCC4 • GATA3 • PARP2 • SDHA
|
FGFR2 fusion • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation
Phase N/A
Masonic Cancer Center, University of Minnesota
Recruiting
Last update posted :
05/24/2021
Initiation :
10/20/2011
Primary completion :
03/01/2022
Completion :
03/01/2024
MYCN • CD34
|
MYCN amplification • LDH elevation
|
cisplatin • carboplatin • paclitaxel • ifosfamide • etoposide IV • melphalan • mesna • busulfan • thiotepa • ursodeoxycholic acid
Phase 2
Mirati Therapeutics Inc.
Active, not recruiting
Last update posted :
05/19/2021
Initiation :
10/10/2018
Primary completion :
04/27/2020
Completion :
05/11/2023
PD-L1 • CD8 • CD4
|
PD-L1 expression
|
Opdivo (nivolumab) • sitravatinib (MGCD516)
Phase 1
GlaxoSmithKline
Completed
Last update posted :
05/18/2021
Initiation :
09/11/2015
Primary completion :
04/29/2020
Completion :
04/29/2020
PD-L1 • MSI
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • GSK3174998
Phase 
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Recruiting
Last update posted :
05/18/2021
Initiation :
11/29/2018
Primary completion :
11/29/2021
Completion :
11/29/2021
TMB
|
Opdivo (nivolumab)
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
05/17/2021
Initiation :
06/12/2012
Primary completion :
11/29/2018
ER • AFP
|
Istodax (romidepsin)
Phase 1
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
05/13/2021
Initiation :
05/29/2018
Primary completion :
12/31/2021
Completion :
12/31/2021
PD-L1
|
Darzalex IV (daratumumab)
Phase N/A
Centre Hospitalier Universitaire de Saint Etienne
Recruiting
Last update posted :
05/13/2021
Initiation :
01/29/2020
Primary completion :
08/01/2024
Completion :
08/01/2024
CD9 • CA9
Phase 2
Eisai Inc.
Active, not recruiting
Last update posted :
05/13/2021
Initiation :
08/17/2017
Primary completion :
02/14/2020
Completion :
09/30/2022
PD-L1 • PD-1
|
everolimus • lenvatinib
Phase N/A
Sohag University
Completed
Last update posted :
05/07/2021
Initiation :
01/01/2020
Primary completion :
06/30/2020
Completion :
12/30/2020
BIRC5
|
BIRC5 expression • BIRC5 overexpression
Phase 1/2
Sarcoma Oncology Research Center, LLC
Recruiting
Last update posted :
05/07/2021
Initiation :
08/24/2017
Primary completion :
12/01/2021
Completion :
04/01/2022
PD-L1 • MSI
|
MSI-H/dMMR
|
Opdivo (nivolumab) • sirolimus • Fyarro (nanoparticle albumin-bound rapamycin)
Phase 1
Xencor, Inc.
Recruiting
Last update posted :
04/29/2021
Initiation :
07/10/2018
Primary completion :
02/28/2022
Completion :
02/28/2023
HER-2 • ER • PGR • MSI
|
MSI-H/dMMR • HER-2 negative
|
vudalimab (XmAb717)
Phase 2
Association Pour La Recherche des Thérapeutique...
Completed
Last update posted :
04/26/2021
Initiation :
05/31/2017
Primary completion :
02/15/2021
Completion :
02/15/2021
CD8 • PD-1 • TFE3 • TFEB
|
TFEB translocation
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Sutent (sunitinib) • Votrient (pazopanib)
Phase 2
Case Comprehensive Cancer Center
Recruiting
Last update posted :
04/20/2021
Initiation :
08/03/2017
Primary completion :
10/01/2021
Completion :
10/01/2021
IL2
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
Phase 3
Merck Sharp & Dohme Corp.
Active, not recruiting
Last update posted :
04/20/2021
Initiation :
06/09/2017
Primary completion :
12/14/2020
Completion :
12/28/2025
PD-L1
|
PD-L1 expression
|
Keytruda (pembrolizumab)
Phase 2
AstraZeneca
Completed
Last update posted :
04/19/2021
Initiation :
04/30/2014
Primary completion :
04/14/2016
Completion :
04/20/2020
MET • IL2
|
Orpathys (savolitinib)
Phase 1/2
Treadwell Therapeutics, Inc
Recruiting
Last update posted :
04/07/2021
Initiation :
08/31/2020
Primary completion :
12/01/2021
Completion :
06/01/2024
MSI
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • CFI-402411
Phase 1/2
National Cancer Institute (NCI)
Completed
Last update posted :
04/06/2021
Initiation :
06/03/2005
Primary completion :
03/14/2017
Completion :
03/14/2017
IL2
|
Nexavar (sorafenib) • gemcitabine • capecitabine
Phase 2
Rahul Aggarwal
Recruiting
Last update posted :
04/06/2021
Initiation :
01/17/2019
Primary completion :
12/31/2023
Completion :
12/31/2023
ATM • ARID1A • UGT1A1
|
ATM mutation • ATM expression • UGT1A1*1*1
|
Lynparza (olaparib) • ceralasertib (AZD6738)
Phase 2
University of Southern California
Recruiting
Last update posted :
04/05/2021
Initiation :
07/19/2017
Primary completion :
07/19/2022
Completion :
07/19/2023
PD-L1
|
Inlyta (axitinib) • ivuxolimab (PF-04518600)
Phase 1
Jonsson Comprehensive Cancer Center
Recruiting
Last update posted :
04/05/2021
Initiation :
11/05/2019
Primary completion :
06/01/2030
Completion :
10/17/2031
FOLH1 • FAP
|
FOLH1 expression
|
FAPI-46
Phase 1/2
BeiGene
Recruiting
Last update posted :
04/02/2021
Initiation :
05/25/2020
Primary completion :
03/26/2025
Completion :
04/26/2025
PD-L1 • MSI
|
MSI-H/dMMR
|
Baize’an (tislelizumab) • Brukinsa (zanubrutinib) • BGB-10188
Phase 1a/1b
BeiGene
Completed
Last update posted :
04/01/2021
Initiation :
06/02/2015
Primary completion :
08/12/2020
Completion :
08/12/2020
EGFR • PD-L1 • ALK • MSI
|
EGFR mutation • MSI-H/dMMR • ALK rearrangement
|
Baize’an (tislelizumab)
Phase 1
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
03/29/2021
Initiation :
03/07/2017
Primary completion :
03/31/2021
Completion :
03/31/2022
IL17A
|
cisplatin • Imfinzi (durvalumab) • tremelimumab (CP-675206)
Phase 1
Dr. Ronnie Shapira
Recruiting
Last update posted :
03/24/2021
Initiation :
02/24/2020
Primary completion :
12/30/2021
Completion :
12/30/2022
TNFA
|
Opdivo (nivolumab)
Phase 2
Sunnybrook Health Sciences Centre
Completed
Last update posted :
03/23/2021
Initiation :
05/01/2014
Primary completion :
02/16/2021
Completion :
03/04/2021
IL2
|
Sutent (sunitinib)
Phase 1/2
Bristol-Myers Squibb
Completed
Last update posted :
03/17/2021
Initiation :
09/11/2018
Primary completion :
11/11/2019
Completion :
12/29/2020
MSI • TNFA
|
Opdivo (nivolumab) • BMS-986310
Phase 1
Checkpoint Therapeutics, Inc.
Recruiting
Last update posted :
03/16/2021
Initiation :
09/20/2017
Primary completion :
07/01/2021
Completion :
12/01/2022
MSI
|
MSI-H/dMMR
|
cosibelimab (CK-301)
Phase 2
Sidney Kimmel Comprehensive Cancer Center at Jo...
Recruiting
Last update posted :
03/15/2021
Initiation :
06/03/2019
Primary completion :
03/01/2022
Completion :
03/01/2023
BRCA1 • BRCA2 • BAP1 • CDK12 • RAD51B • BRIP1 • CHEK2 • RAD51C • RAD51D • CHEK1 • RAD54L • BARD1 • FANCL
|
BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • CHEK1 mutation • RAD51 mutation • CHEK1 expression
|
Lynparza (olaparib)
Phase 
Mohamed Abdel-Rahman
Recruiting
Last update posted :
03/11/2021
Initiation :
03/03/2015
Primary completion :
07/01/2026
Completion :
07/01/2026
BAP1
|
BAP1 mutation
Phase 1
Dana-Farber Cancer Institute
Active, not recruiting
Last update posted :
03/11/2021
Initiation :
08/31/2017
Primary completion :
02/28/2023
Completion :
08/31/2024
BRAF
|
BRAF V600E • BRAF V600 • BRAF V600K
|
Keytruda (pembrolizumab) • trebananib (AMG 386)
Phase 1
City of Hope Medical Center
Active, not recruiting
Last update posted :
03/10/2021
Initiation :
06/14/2016
Primary completion :
11/30/2017
Completion :
12/31/2021
TP53 • MSI • PD-1
|
TP53 mutation • TP53 expression • TP53 overexpression
|
Keytruda (pembrolizumab) • p53MVA
Phase 2
UNICANCER
Active, not recruiting
Last update posted :
03/10/2021
Initiation :
06/16/2017
Primary completion :
01/01/2023
Completion :
12/01/2023
PD-L1 • MSI • POLE • VEGFA • CD34 • CD31 • FOXP3
|
PD-L1 underexpression • POLE mutation • FASN-L
|
Opdivo (nivolumab)
Phase 1
OSE Immunotherapeutics
Recruiting
Last update posted :
03/09/2021
Initiation :
04/16/2019
Primary completion :
12/31/2022
Completion :
12/31/2022
SIRPA
|
BI 765063 • ezabenlimab (BI 754091)
Phase 1/2
ImmuneSensor Therapeutics Inc.
Recruiting
Last update posted :
03/05/2021
Initiation :
09/23/2019
Primary completion :
02/16/2023
Completion :
02/16/2023
PD-L1
|
HR negative
|
IMSA101
Phase 1
Patrick Ott, MD
Recruiting
Last update posted :
03/03/2021
Initiation :
03/03/2019
Primary completion :
12/31/2022
Completion :
09/30/2024
IFNG
|
Yervoy (ipilimumab) • Neo Vax (NEO-PV-01)
Phase 1/2
Beth Israel Deaconess Medical Center
Active, not recruiting
Last update posted :
03/03/2021
Initiation :
10/01/2004
Primary completion :
12/01/2014
Completion :
12/01/2021
CSF2
|
Dendritic cell renal cell carcinoma fusion vaccine
Phase 2
Gustave Roussy, Cancer Campus, Grand Paris
Not yet recruiting
Last update posted :
03/03/2021
Initiation :
03/01/2021
Primary completion :
03/01/2024
Completion :
03/01/2027
HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • PBRM1 • CDK12 • BRIP1 • CHEK2 • FANCA • RAD51 • RAD51C • RAD51D • ARID2 • RAD54L • BARD1 • NBN
|
HER-2 positive • HER-2 amplification • DDR • CDK12 mutation • PBRM1 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • BARD1 mutation • NBN mutation
|
Zejula (niraparib) • Jemperli (dostarlimab)
Phase 2
Istituto Scientifico Romagnolo per lo Studio e ...
Recruiting
Last update posted :
02/26/2021
Initiation :
07/09/2012
Primary completion :
06/01/2021
Completion :
06/01/2022
IL2
Phase 2
Beth Israel Deaconess Medical Center
Completed
Last update posted :
02/24/2021
Initiation :
03/01/2009
Primary completion :
01/01/2018
Completion :
06/01/2018
mTOR
|
MTOR mutation
|
everolimus
Phase 1/2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
02/24/2021
Initiation :
10/29/2009
Primary completion :
05/22/2019
mTOR • IL2RA • CD4
|
entinostat (SNDX-275) • Proleukin (aldesleukin)
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
02/22/2021
Initiation :
02/02/2017
Primary completion :
11/30/2023
Completion :
11/30/2023
TNFRSF9
|
Opdivo (nivolumab)
Phase 2
Millennium Pharmaceuticals, Inc.
Completed
Last update posted :
02/19/2021
Initiation :
06/30/2016
Primary completion :
02/03/2020
Completion :
10/13/2020
IL2
|
everolimus • sapanisertib (TAK-228) • serabelisib (MLN1117)
Phase N/A
Aalborg University Hospital
Recruiting
Last update posted :
02/16/2021
Initiation :
12/23/2020
Primary completion :
06/30/2022
Completion :
09/30/2022
KIM1 • LCN2
Phase 1/2
Incyte Corporation
Completed
Last update posted :
02/16/2021
Initiation :
07/17/2014
Primary completion :
11/26/2018
Completion :
11/06/2020
HER-2 • BRAF • ALK • ER • PGR • MSI
|
BRAF V600E • EGFR mutation • MSI-H/dMMR • BRAF V600 • HER-2 negative • ALK positive • ALK fusion
|
Keytruda (pembrolizumab) • epacadostat (INCB024360)
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
02/11/2021
Initiation :
07/08/2013
Primary completion :
04/18/2016
ALB
|
Sutent (sunitinib) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
Phase 2
Australian and New Zealand Urogenital and Prost...
Recruiting
Last update posted :
02/10/2021
Initiation :
04/11/2019
Primary completion :
04/30/2022
Completion :
04/30/2024
TFE3
|
TFE3 translocation
|
Cabometyx (cabozantinib tablet)
Phase 2
Australian and New Zealand Urogenital and Prost...
Active, not recruiting
Last update posted :
02/09/2021
Initiation :
10/19/2017
Primary completion :
12/01/2021
Completion :
12/01/2022
TFE3
|
TFE3 translocation
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
Phase N/A
Centre Leon Berard
Recruiting
Last update posted :
02/08/2021
Initiation :
12/21/2018
Primary completion :
06/01/2023
Completion :
12/01/2023
IFNG • CD73 • IL2RA • CD69 • IL10 • NCAM1 • ENTPD1
|
Opdivo (nivolumab) • Sutent (sunitinib)
Phase 3
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
02/05/2021
Initiation :
02/12/2021
Primary completion :
12/23/2024
Completion :
12/23/2024
PD-L1 • PD-1
|
lenvatinib • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • Welireg (belzutifan)
Phase 2
H. Lee Moffitt Cancer Center and Research Insti...
Active, not recruiting
Last update posted :
02/04/2021
Initiation :
04/25/2017
Primary completion :
03/26/2019
Completion :
03/01/2021
IL2
|
Keytruda (pembrolizumab) • Proleukin (aldesleukin)
Phase N/A
Charite University, Berlin, Germany
Completed
Last update posted :
01/27/2021
Initiation :
11/01/2015
Primary completion :
02/01/2019
Completion :
03/01/2020
VEGFC
|
Sutent (sunitinib)
Phase 1b/2a
Ocellaris Pharma, Inc.
Recruiting
Last update posted :
01/27/2021
Initiation :
10/06/2020
Primary completion :
11/01/2022
Completion :
11/01/2022
HER-2 • ALK • ER • PGR • ROS1
|
HER-2 negative • ALK fusion • ALK mutation • ROS1 fusion
|
OC-001
Phase N/A
City of Hope Medical Center
Recruiting
Last update posted :
01/26/2021
Initiation :
11/11/2016
Primary completion :
06/11/2022
Completion :
06/11/2022
STAT3
Phase 1
Abramson Cancer Center of the University of Pen...
Recruiting
Last update posted :
01/22/2021
Initiation :
08/26/2020
Primary completion :
08/01/2022
Completion :
08/01/2022
PD-L1
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • capecitabine
Phase 1/2
Fox Chase Cancer Center
Recruiting
Last update posted :
01/20/2021
Initiation :
06/12/2017
Primary completion :
04/06/2023
Completion :
04/06/2024
PD-L1
|
PD-L1 expression
|
Opdivo (nivolumab) • Inlyta (axitinib)
Phase 1
Matthew Dallos
Recruiting
Last update posted :
01/14/2021
Initiation :
08/15/2019
Primary completion :
12/01/2021
Completion :
12/01/2022
CD4
|
spartalizumab (PDR001) • Ilaris (canakinumab)
Phase 2
Toni Choueiri, MD
Active, not recruiting
Last update posted :
01/07/2021
Initiation :
09/26/2017
Primary completion :
11/30/2021
Completion :
11/30/2024
ALB
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
Phase N/A
UNC Lineberger Comprehensive Cancer Center
Completed
Last update posted :
01/07/2021
Initiation :
08/01/2012
Primary completion :
11/01/2014
Completion :
01/01/2019
PBRM1 • KMT2D • HIF1A • SETD2 • MLL2
|
KMT2D mutation • VHL mutation • PBRM1 mutation • HIF1A expression
Phase 2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
01/06/2021
Initiation :
05/15/2018
Primary completion :
07/31/2022
Completion :
07/31/2022
mTOR
|
Sutent (sunitinib) • Cabometyx (cabozantinib tablet)
Phase 2
European Organisation for Research and Treatmen...
Active, not recruiting
Last update posted :
12/25/2020
Initiation :
09/01/2012
Primary completion :
12/06/2017
Completion :
12/01/2025
ALK • MET
|
Xalkori (crizotinib)
Phase 1/2
Peter MacCallum Cancer Centre, Australia
Completed
Last update posted :
12/23/2020
Initiation :
10/20/2016
Primary completion :
05/22/2020
Completion :
05/22/2020
ALB
|
Keytruda (pembrolizumab)
Phase 1a/1b
Spring Bank Pharmaceuticals, Inc.
Recruiting
Last update posted :
12/22/2020
Initiation :
09/23/2019
Primary completion :
12/01/2021
Completion :
05/01/2022
BRAF
|
BRAF mutation
|
Tecentriq (atezolizumab) • SB 11285
Phase 1
Moshe Ornstein
Completed
Last update posted :
12/22/2020
Initiation :
12/20/2016
Primary completion :
11/06/2020
Completion :
11/06/2020
CD8
|
Imfinzi (durvalumab) • tremelimumab (CP-675206)
Phase 1
Yale University
Recruiting
Last update posted :
12/22/2020
Initiation :
06/09/2018
Primary completion :
05/01/2022
Completion :
10/01/2024
EGFR • BRAF • PD-L1
|
EGFR mutation • EGFR T790M • ALK rearrangement
|
Opdivo (nivolumab) • cabiralizumab (BMS-986227) • sotigalimab (APX005M)
Phase 1
Novartis Pharmaceuticals
Completed
Last update posted :
12/21/2020
Initiation :
05/01/2010
Primary completion :
12/01/2013
Completion :
12/01/2013
IL2
|
everolimus
Phase 1
Sukeshi Patel
Active, not recruiting
Last update posted :
12/14/2020
Initiation :
11/01/2009
Primary completion :
12/05/2017
Completion :
09/01/2021
KRAS
|
KRAS mutation
|
Zolinza (vorinostat) • hydroxychloroquine
Phase 
Frede Donskov
Recruiting
Last update posted :
12/09/2020
Initiation :
11/01/2020
Primary completion :
12/31/2022
Completion :
11/01/2023
PD-1 • UGT1A1 • CTLA4
|
UGT1A1*1*1
|
Opdivo (nivolumab) • Sutent (sunitinib)
Phase 1/2
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
12/08/2020
Initiation :
06/28/2012
Primary completion :
12/31/2021
Completion :
12/31/2022
IL2
|
Proleukin (aldesleukin)
Phase 1
Incyte Corporation
Active, not recruiting
Last update posted :
12/04/2020
Initiation :
01/25/2016
Primary completion :
11/07/2019
Completion :
12/24/2021
EGFR • ALK • FOXP3
|
EGFR mutation • ALK translocation
|
Keytruda (pembrolizumab) • parsaclisib (INCB50465) • itacitinib (INCB039110)
Phase 2
University of California, San Francisco
Recruiting
Last update posted :
11/26/2020
Initiation :
11/13/2020
Primary completion :
09/01/2023
Completion :
09/01/2025
ALB
|
Keytruda (pembrolizumab) • Inlyta (axitinib)
Phase N/A
Giselle SaulnierSholler
Active, not recruiting
Last update posted :
11/18/2020
Initiation :
06/01/2014
Primary completion :
06/01/2025
Completion :
06/01/2026
MYCN
|
MYCN amplification
Phase 1
Bristol-Myers Squibb
Completed
Last update posted :
10/29/2020
Initiation :
08/11/2011
Primary completion :
12/01/2014
Completion :
05/22/2019
IFNG • CXCL10 • CXCL9 • CD4
|
Opdivo (nivolumab)
Phase 2
AVEO Pharmaceuticals, Inc.
Completed
Last update posted :
10/27/2020
Initiation :
01/01/2011
Primary completion :
10/01/2012
Completion :
10/01/2012
HGF • IL2 • CA9 • VEGFB • VEGFD • CD68 • VEGFC
|
Fotivda (tivozanib)
Phase 1/2
Shanghai Public Health Clinical Center
Recruiting
Last update posted :
10/21/2020
Initiation :
03/01/2017
Primary completion :
12/31/2021
Completion :
06/30/2022
CD8 • CD4
Phase 2
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
10/21/2020
Initiation :
01/01/2011
Primary completion :
01/01/2021
Completion :
01/01/2022
ALB
|
Avastin (bevacizumab) • everolimus • Votrient (pazopanib)
Phase 3b
Bristol-Myers Squibb
Active, not recruiting
Last update posted :
10/19/2020
Initiation :
04/29/2019
Primary completion :
08/22/2021
Completion :
04/19/2025
PD-L1
|
PD-L1 expression
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
Phase N/A
University of Dundee
Recruiting
Last update posted :
10/19/2020
Initiation :
01/10/2020
Primary completion :
07/30/2021
Completion :
12/31/2021
KIT
|
BRAF mutation
Phase 1/2
GB006, Inc., a wholly owned subsidiary of Gossa...
Recruiting
Last update posted :
10/16/2020
Initiation :
08/13/2019
Primary completion :
03/01/2023
Completion :
03/01/2023
PD-L1
|
Keytruda (pembrolizumab) • gemcitabine • Abraxane (albumin-bound paclitaxel) • GB1275
Phase 2
Oxford BioMedica
Completed
Last update posted :
10/16/2020
Initiation :
08/01/2004
Primary completion :
07/01/2008
Completion :
07/01/2008
IL2
|
TroVax (MVA 5T4)
Phase 1
Genentech, Inc.
Completed
Last update posted :
10/08/2020
Initiation :
07/11/2012
Primary completion :
02/26/2020
Completion :
02/26/2020
HER-2 • ER • PGR • MSI
|
MSI-H/dMMR
|
Avastin (bevacizumab) • carboplatin • Tecentriq (atezolizumab) • 5-fluorouracil • Abraxane (albumin-bound paclitaxel) • oxaliplatin • pemetrexed • leucovorin calcium
Phase 1
Shanghai Junshi Bioscience Co., Ltd.
Active, not recruiting
Last update posted :
09/30/2020
Initiation :
03/31/2017
Primary completion :
12/31/2019
Completion :
12/01/2020
PD-1
|
Tuoyi (toripalimab) • Inlyta (axitinib)
Phase 1b
Pfizer
Completed
Last update posted :
09/24/2020
Initiation :
02/26/2014
Primary completion :
02/22/2017
Completion :
09/05/2019
MET • HGF • FLT4
|
MET positive
|
Xalkori (crizotinib) • Inlyta (axitinib)
Phase 2
Sidney Kimmel Comprehensive Cancer Center at Jo...
Completed
Last update posted :
09/15/2020
Initiation :
05/01/2015
Primary completion :
12/01/2018
Completion :
12/01/2018
IGF1 • IGFBP3
|
metformin
Phase 2
Roberto Pili
Active, not recruiting
Last update posted :
09/14/2020
Initiation :
05/24/2018
Primary completion :
04/01/2023
Completion :
04/01/2024
IL2
|
entinostat (SNDX-275) • Proleukin (aldesleukin)
Phase 1b
Hutchison Medipharma Limited
Recruiting
Last update posted :
09/14/2020
Initiation :
04/25/2019
Primary completion :
03/01/2021
Completion :
07/01/2021
IL2 • IFNA1
|
MSI-H/dMMR
|
Tyvyt (sintilimab) • Elunate (fruquintinib)
Phase N/A
National Cancer Institute, Naples
Recruiting
Last update posted :
09/11/2020
Initiation :
12/01/2016
Primary completion :
06/01/2021
Completion :
06/01/2021
PD-L1 • IFNG • CD73 • IL10 • ENTPD1 • FOXP3
|
Opdivo (nivolumab)
Phase 2
Jonsson Comprehensive Cancer Center
Completed
Last update posted :
09/01/2020
Initiation :
04/01/2006
Primary completion :
07/01/2009
Completion :
07/01/2009
VHL
|
bortezomib
Phase 3
Bristol-Myers Squibb
Active, not recruiting
Last update posted :
08/24/2020
Initiation :
09/27/2012
Primary completion :
05/06/2015
Completion :
12/23/2020
PD-L1
|
PD-L1 expression
|
Opdivo (nivolumab) • everolimus
Phase 1
Shijiazhuang Yiling Pharmaceutical Co. Ltd
Recruiting
Last update posted :
08/21/2020
Initiation :
12/19/2018
Primary completion :
12/01/2020
Completion :
12/01/2020
KDR
|
XY0206
Phase 1a/1b
Five Prime Therapeutics, Inc.
Completed
Last update posted :
07/31/2020
Initiation :
09/01/2015
Primary completion :
11/18/2019
Completion :
11/18/2019
CD8 • CD68
|
Opdivo (nivolumab) • cabiralizumab (BMS-986227)
Phase 1
Philogen S.p.A.
Recruiting
Last update posted :
07/15/2020
Initiation :
07/01/2020
Primary completion :
06/01/2022
Completion :
06/01/2022
MSI
|
MSI-H/dMMR
|
dodekin (F8-IL12)
Phase 1/2
Megan Daly, MD
Recruiting
Last update posted :
07/13/2020
Initiation :
05/20/2019
Primary completion :
07/01/2021
Completion :
07/01/2023
PD-L1
|
Keytruda (pembrolizumab)
Phase N/A
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
07/01/2020
Initiation :
01/01/2013
Primary completion :
06/30/2020
Completion :
06/30/2020
BAP1
|
BAP1 mutation
Phase 1/2
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
06/17/2020
Initiation :
04/23/2017
Primary completion :
04/23/2023
Completion :
04/24/2024
IL2
|
Opdivo (nivolumab) • sitravatinib (MGCD516)
Phase 1/2
Children's Oncology Group
Completed
Last update posted :
06/09/2020
Initiation :
09/21/2009
Primary completion :
12/31/2018
Completion :
12/31/2018
ALK • MET • HGF
|
MET amplification • ALK fusion • ALK mutation • MET mutation • ALK amplification
|
Xalkori (crizotinib)
Phase 1
Emory University
Completed
Last update posted :
05/29/2020
Initiation :
04/01/2011
Primary completion :
08/09/2017
Completion :
08/09/2017
AFP
|
sirolimus
Phase N/A
Ilene Sussman, PhD
Recruiting
Last update posted :
05/19/2020
Initiation :
01/01/2012
Primary completion :
12/01/2024
Completion :
12/01/2024
SDHB
Phase 2
Children's Oncology Group
Completed
Last update posted :
05/13/2020
Initiation :
02/01/2011
Primary completion :
12/31/2015
Completion :
06/30/2019
SMARCD3
|
alisertib (MLN8237)
Phase 2
West China Hospital
Not yet recruiting
Last update posted :
05/13/2020
Initiation :
06/01/2020
Primary completion :
12/01/2021
Completion :
06/01/2022
ALB
|
Tuoyi (toripalimab) • Inlyta (axitinib)
Phase 2
West China Hospital
Not yet recruiting
Last update posted :
05/12/2020
Initiation :
06/01/2020
Primary completion :
06/01/2022
Completion :
04/01/2023
ALB
|
Tyvyt (sintilimab)
Phase N/A
Washington University School of Medicine
Completed
Last update posted :
05/07/2020
Initiation :
08/01/2016
Primary completion :
01/02/2020
Completion :
01/02/2020
AQP1 • PLIN2
Phase 1
Bristol-Myers Squibb
Active, not recruiting
Last update posted :
04/22/2020
Initiation :
01/25/2012
Primary completion :
02/02/2016
Completion :
06/30/2021
IL2 • IFNA1
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Sutent (sunitinib) • Votrient (pazopanib)
Phase 1
NCIC Clinical Trials Group
Completed
Last update posted :
04/08/2020
Initiation :
03/06/2003
Primary completion :
03/09/2006
Completion :
12/21/2009
CLU
|
docetaxel • custirsen (OGX-011)
Phase 1/2
Shanghai Sinobioway Sunterra Biotech
Active, not recruiting
Last update posted :
04/07/2020
Initiation :
03/26/2018
Primary completion :
01/30/2021
Completion :
03/30/2035
AXL
|
fludarabine IV • CCT301-38 • CCT301-59
Phase 1
Emory University
Completed
Last update posted :
04/03/2020
Initiation :
02/01/2015
Primary completion :
09/22/2019
Completion :
09/22/2019
STAT3 • IL6R
|
topotecan • simvastatin • cyclophosphamide intravenous
Phase 1
Millennium Pharmaceuticals, Inc.
Completed
Last update posted :
04/01/2020
Initiation :
01/04/2010
Primary completion :
02/07/2019
Completion :
02/07/2019
EIF4EBP1 • RPS6
|
sapanisertib (TAK-228)
Phase 2
Mark Stein
Recruiting
Last update posted :
03/26/2020
Initiation :
03/01/2020
Primary completion :
05/01/2026
Completion :
02/01/2027
ALB
|
Opdivo (nivolumab) • Cabometyx (cabozantinib tablet)
Phase 1
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
03/23/2020
Initiation :
11/25/2014
Primary completion :
05/21/2020
Completion :
05/21/2020
IL17A
|
Opdivo (nivolumab) • Avastin (bevacizumab) • Yervoy (ipilimumab) • MIL 60 (bevacizumab biosimilar)
Phase 1
Pfizer
Completed
Last update posted :
03/17/2020
Initiation :
06/21/2011
Primary completion :
02/20/2019
Completion :
02/20/2019
CD20
|
CD20 positive
|
Rituxan (rituximab) • utomilumab (PF-05082566)
Phase 1
Osaka University
Completed
Last update posted :
03/06/2020
Initiation :
03/01/2016
Primary completion :
03/01/2020
Completion :
03/01/2020
FOXP3
|
Opdivo (nivolumab) • Poteligeo (mogamulizumab)
Phase 2
Barbara Ann Karmanos Cancer Institute
Completed
Last update posted :
03/05/2020
Initiation :
01/01/2006
Primary completion :
03/01/2010
Completion :
03/01/2010
CSF2
|
Leukine (sargramostim)
Phase 2b
The Rogosin Institute
Completed
Last update posted :
03/05/2020
Initiation :
01/01/2014
Primary completion :
03/01/2019
Completion :
03/01/2019
Cancer antigen 19-9
Phase 2
M.D. Anderson Cancer Center
Completed
Last update posted :
03/04/2020
Initiation :
10/01/2013
Primary completion :
01/18/2019
Completion :
01/18/2019
VHL
|
VHL mutation
|
carfilzomib
Phase 2
Providence Health & Services
Recruiting
Last update posted :
03/03/2020
Initiation :
12/01/2014
Primary completion :
01/01/2022
Completion :
06/01/2025
IL2
|
Proleukin (aldesleukin)
Phase N/A
Eli Lilly and Company
No Longer Available
Last update posted :
03/02/2020
IL10
|
pegilodecakin (LY3500518) • Prevascar (ilodecakin)
Phase 2
Gustave Roussy, Cancer Campus, Grand Paris
Recruiting
Last update posted :
02/19/2020
Initiation :
10/17/2016
Primary completion :
10/01/2020
Completion :
10/01/2020
ALK • MSI
|
Tecentriq (atezolizumab)
Phase 1/2
The Christie NHS Foundation Trust
Not yet recruiting
Last update posted :
02/10/2020
Initiation :
03/01/2020
Primary completion :
02/01/2022
Completion :
02/01/2023
PD-L1
|
Keytruda (pembrolizumab) • cyclophosphamide oral • cyclophosphamide intravenous
Phase 1
EMD Serono
Completed
Last update posted :
01/29/2020
Initiation :
01/31/2013
Primary completion :
12/16/2019
Completion :
12/16/2019
PD-L1
|
PD-L1 expression
|
Bavencio (avelumab)
Phase 1/2
Fred Hutchinson Cancer Research Center
Completed
Last update posted :
01/17/2020
Initiation :
09/01/2003
Primary completion :
01/01/2006
HLA-DRB1 • HLA-DQB1
|
fludarabine IV • cyclosporin A microemulsion • mycophenolate mofetil • peripheral blood stem cell transplantation
Phase 1
MacroGenics
Completed
Last update posted :
01/09/2020
Initiation :
07/01/2011
Primary completion :
04/18/2019
Completion :
04/18/2019
CD276
|
CD276 overexpression
|
enoblituzumab (MGA271)
Phase N/A
Institut Paoli-Calmettes
Recruiting
Last update posted :
01/09/2020
Initiation :
05/29/2017
Primary completion :
12/13/2022
Completion :
12/13/2022
MMP2 • MMP9
Phase 1
Fate Therapeutics
Active, not recruiting
Last update posted :
01/08/2020
Initiation :
01/18/2018
Primary completion :
10/01/2021
Completion :
10/01/2022
EGFR • HER-2
|
Herceptin (trastuzumab) • Erbitux (cetuximab) • FATE-NK100
Phase N/A
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
01/07/2020
Initiation :
09/01/1994
Primary completion :
09/30/2020
Completion :
09/30/2020
MSH2
Phase 1/2
Leonard Appleman
Completed
Last update posted :
12/31/2019
Initiation :
03/01/2012
Primary completion :
02/06/2018
Completion :
02/01/2019
IL2
|
hydroxychloroquine • Proleukin (aldesleukin)
Phase 1
Inge Marie Svane
Recruiting
Last update posted :
12/23/2019
Initiation :
12/01/2016
Primary completion :
12/01/2020
Completion :
12/01/2020
IL2
|
fludarabine IV • Proleukin (aldesleukin) • cyclophosphamide intravenous
Phase 1/2
Fred Hutchinson Cancer Research Center
Completed
Last update posted :
12/20/2019
Initiation :
08/01/2001
Primary completion :
09/01/2004
Completion :
09/05/2004
HLA-DRB1
|
fludarabine IV • cyclosporin A microemulsion • mycophenolate mofetil • peripheral blood stem cell transplantation
Phase 1/2
Shenzhen BinDeBio Ltd.
Recruiting
Last update posted :
12/11/2019
Initiation :
03/01/2018
Primary completion :
03/01/2023
Completion :
03/01/2023
MET • CD19 • MSLN • CTAG1B • HLA-A • CD22 • CD33
|
CD19 expression • HLA-A*02:01 positive • HLA-A positive
|
CAR-T cell immunotherapy • multi-target gene-modified CAR-T/TCR-T cell immunotherapy
Phase 1/2
N.N. Petrov National Medical Research Center of...
Completed
Last update posted :
12/06/2019
Initiation :
01/31/2001
Primary completion :
12/31/2018
Completion :
12/31/2018
VEGFA • IL2RA • TGFB1 • IL10
Phase 1b/2
HUYA Bioscience International
Recruiting
Last update posted :
11/01/2019
Initiation :
08/01/2016
Primary completion :
10/01/2021
Completion :
01/01/2022
EGFR • PD-L1 • ALK
|
Opdivo (nivolumab) • Epidaza (chidamide)
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
10/29/2019
Initiation :
07/09/2006
Primary completion :
01/20/2010
Completion :
01/20/2010
ALB
|
fresolimumab (GC 1008)
Phase 3
AVEO Pharmaceuticals, Inc.
Completed
Last update posted :
10/28/2019
Initiation :
12/01/2009
Primary completion :
07/01/2012
Completion :
06/01/2013
IL2
|
Nexavar (sorafenib) • Fotivda (tivozanib)
Phase N/A
Fred Hutchinson Cancer Research Center
Completed
Last update posted :
09/10/2019
Initiation :
11/01/1999
Primary completion :
07/01/2002
HLA-DRB1
|
fludarabine IV • cyclosporin A microemulsion • mycophenolate mofetil • peripheral blood stem cell transplantation